Deep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)

eLearning module_Deep dive on SGLT2 inhibitors_index image

This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.

View Jardiance® (empagliflozin) prescribing and adverse event reporting information for:

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage